This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Pulmonary function testing (PFT) has a long and rich history in the definition, diagnosis, and management of COPD. For decades, spirometry has been regarded as the standard for diagnosing COPD; however, numerous studies have shown that COPD symptoms, pathology, and associated poor outcomes can occur, despite normal spirometry. Diffusing capacity and imaging studies have called into question the need for spirometry to put the “O” (obstruction) in COPD. The role of exercise testing and the ability of PFTs to phenotype COPD are reviewed. Although PFTs play an important role in diagnosis, treatment decisions are primarily determined by symptom intensity and exacerbation history. Although a seminal study positioned FEV1 as the primary predictor of survival, numerous studies have shown that tests other than spirometry are superior predictors of mortality. In years past, using spirometry to screen for COPD was promulgated; however, this only seems appropriate for individuals who are symptomatic and at risk for developing COPD.
- pulmonary disease
- chronic obstructive
- diagnosis
- spirometry
- pulmonary diffusing capacity
- respiratory function tests
- exercise test
Footnotes
- Correspondence: Jeffrey M Haynes RRT RPFT FAARC, Pulmonary Function Laboratory, Elliot Health System, 185 Queen City Avenue, Manchester, NH 03101. E-mail: jhaynes{at}elliot-hs.org
A version of this paper was presented by Mr Haynes at the 59th Respiratory Care Journal Conference COPD: Current Evidence and Implications for Practice, held June 21–22, 2022, in St Petersburg, Florida.
Mr Haynes discloses a relationship with Morgan Scientific. Dr Kaminsky discloses relationships with MGC Diagnostics and UptoDate. Mr Ruppel discloses a relationship with MGC Diagnostics and the National Board for Respiratory Care.
- Copyright © 2023 by Daedalus Enterprises
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$30.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.